BACKGROUNDBarry N. Silberg, M.D., F.A.C.S., is the Executive Director of the Santa Rosa Antibiotic Effectiveness Project, Inc., and is the investigator-sponsor of the current study.
treatmentA promising new treatment for soft tissue infection, including Methicillin-resistant Staphylococcus Aureus (MRSA).
CURRENT STUDYAn FDA and WIRB approved expanded access study is currently in progress at Palm Drive Hospital, Sebastopol, California.
Promising new technology
The Santa Rosa Antibiotic Effectiveness Project is a 501(c)(3) nonprofit corporation that has been formed to advance the science of antibiotic medicine and to educate the public about our research in antibiotic effectiveness, which will benefit individuals and the community.
A study for direct antibiotic delivery, which offers a promising new way to treat soft tissue infections, including Methicillin-resistant Staphylococcus Aureus (MRSA), was approved on January 14, 2014, and the first group of patients were completed at Palm Drive Hospital, Sebastopol, California. No new patients are being accepted into the study at this time because of the closure of Palm Drive Hospital at the end of April, 2014. We are in the process of obtaining FDA and IRB approval for the new hospital location. Please check back for status updates.
FDA and Western Institutional Review Board (WIRB) approves new Expanded Access Study - Intermediate Population at Palm Drive Hospital, 501 Petaluma Avenue, Sebastopol, California.